First Time Loading...

Instem PLC
LSE:INS

Watchlist Manager
Instem PLC Logo
Instem PLC
LSE:INS
Watchlist
Price: 830 GBX Market Closed
Updated: Apr 28, 2024
Section:
 

Relative Value

The Relative Value of one INS stock under the Base Case scenario is 1 218.76 GBX. Compared to the current market price of 830 GBX, Instem PLC is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INS Relative Value
Base Case
1 218.76 GBX
Undervaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
22
vs Industry
38
Median 3Y
3.2
Median 5Y
2.5
Industry
2.4
Forward
2.8
More Details
56.1
P/E
P/E
Price to Earnings
56.1
vs History
30
vs Industry
8
Median 3Y
56.1
Median 5Y
30.5
Industry
23.2
Forward
26.1
More Details
22.5
P/OCF
P/OCF
Price to OCF
22.5
vs History
15
vs Industry
18
Median 3Y
20.5
Median 5Y
17.2
Industry
15.5
More Details
43.7
P/FCFE
P/FCFE
Price to FCFE
43.7
vs History
30
vs Industry
14
Median 3Y
43.7
Median 5Y
28.8
Industry
23.5
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
38
vs Industry
25
Median 3Y
3.5
Median 5Y
3.5
Industry
2.2
More Details
3
EV/S
EV/S
Enterprise Value to Sales
3
vs History
19
vs Industry
37
Median 3Y
3
Median 5Y
2.3
Industry
2.5
Forward
2.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
More Details
17.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.7
vs History
19
vs Industry
20
Median 3Y
17.1
Median 5Y
11.9
Industry
12.5
Forward
14.8
More Details
29.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.1
vs History
25
vs Industry
15
Median 3Y
29.1
Median 5Y
19.9
Industry
17.2
Forward
20.2
More Details
21.7
EV/OCF
EV/OCF
Enterprise Value to OCF
21.7
vs History
12
vs Industry
20
Median 3Y
19.1
Median 5Y
16.3
Industry
15.1
More Details
40.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
40.2
vs History
3
vs Industry
13
Median 3Y
30.5
Median 5Y
22.8
Industry
19.7
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
36
vs Industry
31
Median 3Y
2.4
Median 5Y
2.5
Industry
2
More Details

Multiples Across Competitors

INS Competitors Multiples
Instem PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Instem PLC
LSE:INS
190m GBP 3.1 56.1 17.7 29.1
US
Veeva Systems Inc
NYSE:VEEV
32.4B USD 13.7 61.6 61.4 66.1
US
Cerner Corp
NASDAQ:CERN
27.9B USD 4.8 47.3 19.6 38.6
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD 2.6 -116.8 16.5 111.6
JP
M3 Inc
TSE:2413
1.3T JPY 5.4 27.5 14.6 16.4
AU
Pro Medicus Ltd
ASX:PME
11.4B AUD 78.1 163.9 112.7 112.7
US
Inspire Medical Systems Inc
NYSE:INSP
7B USD 11.2 -331.8 -175.3 -162.9
US
Doximity Inc
NYSE:DOCS
4.4B USD 9.5 32.2 21.5 22.9
SE
Sectra AB
STO:SECT B
42.7B SEK 26.1 100.6 -66.2 -66.2
US
Evolent Health Inc
NYSE:EVH
3.1B USD 1.6 -22.1 26.1 277.7
US
Goodrx Holdings Inc
NASDAQ:GDRX
2.8B USD 3.8 -319.5 34.1 -111.3
P/E Multiple
Earnings Growth
UK
Instem PLC
LSE:INS
Average P/E: 69.9
56.1
148%
US
Veeva Systems Inc
NYSE:VEEV
61.6
139%
US
Cerner Corp
NASDAQ:CERN
47.3
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
Negative Multiple: -116.8 N/A
JP
M3 Inc
TSE:2413
27.5
26%
AU
Pro Medicus Ltd
ASX:PME
163.9
119%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -331.8 N/A
US
Doximity Inc
NYSE:DOCS
32.2
79%
SE
Sectra AB
STO:SECT B
100.6
56%
US
Evolent Health Inc
NYSE:EVH
Negative Multiple: -22.1 N/A
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -319.5 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Instem PLC
LSE:INS
Average EV/EBITDA: 36
17.7
70%
US
Veeva Systems Inc
NYSE:VEEV
61.4
221%
US
Cerner Corp
NASDAQ:CERN
19.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
16.5
N/A
JP
M3 Inc
TSE:2413
14.6
24%
AU
Pro Medicus Ltd
ASX:PME
112.7
124%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -175.3 N/A
US
Doximity Inc
NYSE:DOCS
21.5
103%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.2 N/A
US
Evolent Health Inc
NYSE:EVH
26.1
194%
US
Goodrx Holdings Inc
NASDAQ:GDRX
34.1
305%
EV/EBIT Multiple
EBIT Growth
UK
Instem PLC
LSE:INS
Average EV/EBIT: 84.4
29.1
124%
US
Veeva Systems Inc
NYSE:VEEV
66.1
238%
US
Cerner Corp
NASDAQ:CERN
38.6
N/A
US
Change Healthcare Inc
NASDAQ:CHNG
111.6
N/A
JP
M3 Inc
TSE:2413
16.4
N/A
AU
Pro Medicus Ltd
ASX:PME
112.7
110%
US
Inspire Medical Systems Inc
NYSE:INSP
Negative Multiple: -162.9 N/A
US
Doximity Inc
NYSE:DOCS
22.9
116%
SE
Sectra AB
STO:SECT B
Negative Multiple: -66.2 N/A
US
Evolent Health Inc
NYSE:EVH
277.7
2 086%
US
Goodrx Holdings Inc
NASDAQ:GDRX
Negative Multiple: -111.3 N/A

See Also

Summary
INS intrinsic value, competitors valuation, and company profile.
DCF Valuation
INS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INS stock valuation using valuation multiples.
Wall Street Estimates
INS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.